M 108
Alternative Names: FG-M108; M 108Latest Information Update: 13 Jul 2024
At a glance
- Originator FutureGen Biopharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastric cancer; Oesophageal cancer
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase I/IIa trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 25 Dec 2023 Phase-III clinical trials in Gastric cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First line therapy) in China (IV) (NCT06177041)
- 25 Dec 2023 Phase-III clinical trials in Oesophageal cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First line therapy) in China (IV) (NCT06177041)